+1 (855) PLE.XISION (753.9474) info@plexision.com
  • Dedicated To Individual Health
    Personalized medicine and drug development in organ transplantation and immunological disorders.
  • PleximmuneTM
    Predicts the risk of acute cellular rejection after liver or intestine transplantation in children.
  • Cell-Based Biomarkers
    Combined drug-biomarker development for immunological disorders.
  • PlexCMVTM
    Measuring cell mediated immunity to Cytomegalovirus

In the News: PlexCMVTM, measuring cell-mediated immunity to cytomegalovirus....

 
 

Plexision’s first patented product, the PleximmuneTM test, predicts the risk of acute cellular rejection after liver or intestine transplantation in children

Learn More +

Pleximmune FAQs +

The PleximarkTM blood test assesses the likelihood of acute cellular rejection after renal transplantation.

Learn More +

show all Pleximark FAQs

Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development, from preclinical to post- marketing.      

Learn More +

      

Immuno-Oncology is a rapidly growing area of tumor therapy that fights cancer               

  • by recruiting the patient’s immune system, or

  • with drugs that are based on immune mechanisms.

Learn More +

PlexCMVTM is a blood test to measure the level of cellular immunity to Cytomegalovirus (CMV). Decreased anti-CMV immunity increases the risk of CMV infection.   

Learn More +

PlexEBVTM is a lab developed blood test to measure the level of cellular immunity to Epstein-Barr virus (EBV). Decreased anti-EBV immunity increases the risk of EBV infection.  

Learn More +

Immune deficiency can impair cellular or antibody-mediated immune responses and cause recurrent infections and cancers. Our test panel evaluates T-cell dysfunction using mitogen and antigen stimulation.  

Learn More +